首页> 外文会议>International Congress on Coronary Artery Disease >Evaluation of Matrix Metalloproteinase-9 (MMP-9) and its tissue inhibitor of metalloproteinase-1 (Timp-1) in patients with coronary syndromes after percutaneous intervention(PCI)
【24h】

Evaluation of Matrix Metalloproteinase-9 (MMP-9) and its tissue inhibitor of metalloproteinase-1 (Timp-1) in patients with coronary syndromes after percutaneous intervention(PCI)

机译:经皮干预后冠状动脉综合征患者中基质金属蛋白酶-9(MMP-9)及其组织抑制剂及其组织抑制剂(PCI)

获取原文

摘要

Atherosclerosis and inflammation are two key factors in developing coronary artery disease (CAD). The presence of inflammation is reflected by the hs-CRP and MMP-9 produced by macrophages from the atherosclerotic plaques and directs the progression of coronary artery disease to acute coronary syndromes. We aimed to see the relationship between MMP-9, TIMP-1 and hs-CRP in patients with coronary atherosclerosis. MMP-9, TIMP-1 and hs-CRP reflects the presence of inflammation and the evolution of stable atherosclerotic plaques into unstable ones and developing of acute coronary syndromes.
机译:动脉粥样硬化和炎症是开发冠状动脉疾病(CAD)的两个关键因素。炎症的存在由来自动脉粥样硬化斑块的巨噬细胞产生的HS-CRP和MMP-9反映,并引导冠状动脉疾病的进展到急性冠状动脉综合征。我们的目标是在冠状动脉粥样硬化患者中看到MMP-9,TIMP-1和HS-CRP之间的关系。 MMP-9,TIMP-1和HS-CRP反映了炎症的存在和稳定的动脉粥样硬化斑块的进化,急性冠状动脉综合征的不稳定和发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号